Loading
companiesCompany
Immutep
Immutep is an Australian-French company built on the immune checkpoint LAG-3, whose soluble LAG-3 protein eftilagimod alpha is in the phase 3 TACTI-004 trial with pembrolizumab and chemotherapy in first-line non-small-cell lung cancer.
Also called: Immutep S.A.S.Immutep LimitedPrima BioMed
Overview
Immutep, listed in Sydney and on Nasdaq and with research in Paris, develops therapies around LAG-3, a checkpoint discovered by its scientific founder. Its lead, eftilagimod alpha (efti), is a soluble LAG-3 protein that activates antigen-presenting cells through MHC class II rather than blocking a checkpoint, and is combined with PD-1 antibodies and chemotherapy; after phase 2 results in lung and head and neck cancer it began the phase 3 TACTI-004 trial in first-line non-small-cell lung cancer in 2025. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Sydney, AU
Scorecard
All companies#71of 1244 companies, score 61
- approved products +6
- targets +2
- modalities +2
- regions +7
- 24-month regulatory events +14
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 2,094 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
Similar pages
- TreatmentHLX26
Shares LAG-3, Non-small-cell lung cancer.
- TargetVISTA
Shares LAG-3, Non-small-cell lung cancer.
- TrialFianlimab + cemiplimab phase 3 (first-line melanoma)
Shares LAG-3, Pembrolizumab.
- InstitutionIstituto Nazionale Tumori IRCCS Fondazione G. Pascale
Shares LAG-3, Non-small-cell lung cancer.
- InstitutionUPMC Hillman Cancer Center
- TargetTIM-3
Shares LAG-3, Non-small-cell lung cancer.
- PathwayT-cell exhaustion
Shares LAG-3, Pembrolizumab, Non-small-cell lung cancer.
cancers
fronts
targets
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)